Literature DB >> 7851394

Purification from placenta, amino acid sequence, structure comparisons and cDNA cloning of human glutaredoxin.

C A Padilla1, E Martínez-Galisteo, J A Bárcena, G Spyrou, A Holmgren.   

Abstract

Glutaredoxin is generally a glutathione-dependent hydrogen donor for ribonucleotide reductase and also catalyses general glutathione (GSH)-disulfide-oxidoreduction reactions in the presence of NADPH and glutathione reductase. A Glutaredoxin from human placenta was purified to homogeneity, as judged by SDS/PAGE and IEF (12 kDa). Purification was monitored by the activity with hydroxyethyl disulfide as a substrate. Values of pI for glutaredoxin were obtained by IEF; the pI of the protein shifted from 7.3 in its fully reduced state to 9.0 in the oxidized state after treatment with excess hydroxyethyl disulfide. The glutaredoxin preparation showed GSH-dependent hydrogen-donor activity with recombinant mouse ribonucleotide reductase, it exhibited dehydroascorbate reductase activity as well as hydroxyethyl-disulfide-reducing activity. The amino acid sequence (residues 3-104) of glutaredoxin was determined by peptide sequencing and residues 1, 2 and 105 by cDNA sequence analysis. The glutaredoxin sequence comprised the classical active site for glutaredoxins -Cys22-Pro-Tyr-Cys25- and three additional half-cystine residues; two of these in positions 78 and 82. The sequence was similar to other known mammalian glutaredoxins (about 80% identities), with important differences such as one additional Cys residue (Cys7) and no Met residue. The sequence of human glutaredoxin was compared to that of Escherichia coli glutaredoxin with known three-dimensional structure in solution to identify conserved residues and predict a structure from alignment. In particular the GSH-binding site of glutaredoxin was conserved between all molecules. A cDNA that encodes the entire glutaredoxin gene (grx) and flanking sequences was isolated from a human spleen cDNA library. The nucleotide sequence of this cDNA (0.8 kb) was determined, including the complete grx gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7851394     DOI: 10.1111/j.1432-1033.1995.tb20356.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Role of Bim in diallyl trisulfide-induced cytotoxicity in human cancer cells.

Authors:  Byeong-Chel Lee; Bae-Hang Park; Seog-Young Kim; Yong J Lee
Journal:  J Cell Biochem       Date:  2011-01       Impact factor: 4.429

2.  Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal-regulating kinase 1.

Authors:  Jae J Song; Yong J Lee
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

3.  Penultimate selenocysteine residue replaced by cysteine in thioredoxin reductase from selenium-deficient rat liver.

Authors:  Jun Lu; Liangwei Zhong; Maria Elisabet Lönn; Raymond F Burk; Kristina E Hill; Arne Holmgren
Journal:  FASEB J       Date:  2009-04-07       Impact factor: 5.191

4.  Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression.

Authors:  Jae-Hoon Jeong; Jee Young An; Yong Tae Kwon; Juong G Rhee; Yong J Lee
Journal:  J Cell Biochem       Date:  2009-01-01       Impact factor: 4.429

Review 5.  Redoxins as gatekeepers of the transcriptional oxidative stress response.

Authors:  Barbara L Hopkins; Carola A Neumann
Journal:  Redox Biol       Date:  2019-01-14       Impact factor: 11.799

6.  Knockdown of cytosolic glutaredoxin 1 leads to loss of mitochondrial membrane potential: implication in neurodegenerative diseases.

Authors:  Uzma Saeed; Lalitha Durgadoss; R Khader Valli; Dinesh C Joshi; Preeti G Joshi; Vijayalakshmi Ravindranath
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

7.  Redox regulation of metabolic and signaling pathways by thioredoxin and glutaredoxin in NOS-3 overexpressing hepatoblastoma cells.

Authors:  Raúl González; M José López-Grueso; Jordi Muntané; J Antonio Bárcena; C Alicia Padilla
Journal:  Redox Biol       Date:  2015-07-17       Impact factor: 11.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.